Symphony Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/rk19hdm2otdbsczucrtqfah9.pdf

Key Takeaways


The Channel Reset & Summer Setup

Bakeri: "The objective was that even if the company sales is forsaken in the short term, but the channel inventory is normalized. That has, to a great degree, been achieved."

BISP: The Profitability Inflection


New Product Categories: The Cooling Pyramid

Bakeri: "We are taking baby steps in these segments. As explained, we really have no delusions of grandeur. We do not think that we will really be amongst the top players in the country. We are going to grow these categories cautiously so that they remain EBITDA accretive."

International: Growth with Friction


Margins & Capital Allocation

Bakeri: "The major players also have their captive manufacturing, which is probably why... they may not be EBITDA positive, some of them. In our case, this is going to be purely a variable cost business model. We will just spend enough to sort of grow the business and see where it goes."

Guidance & Commitments

CommitmentSpecificsTimeline
Channel inventory normalizationDeliberate destocking largely achieved; channel now primed with fresh summer 2027 inventoryCompleted
BISP EBITDA improvementPotential to improve further from high single-digit percentageMedium term
New product rolloutLaunch in one market first, then expand to become pan-India~1 year from initial launch
New product profitabilityAll new categories to remain EBITDA accretive; profitability-led scaling modelOngoing
H2 standalone EBITDA marginShould be somewhat better than H1 level of 14.4%Q3–Q4 FY27
Dividend policyMaintain existing payout policy; ₹2 interim declaredOngoing
Working capital disciplineLow working capital model maintained for new products, consistent with air cooler philosophyOngoing

Key Metrics

MetricQ2 FY27
Consolidated revenue₹275 cr, +31% YoY
Consolidated EBITDA₹36 cr, vs ₹13 cr YoY
Consolidated EBITDA margin13.0%, vs 6.4% YoY; operating leverage and cost discipline offset 4% gross margin decline
Consolidated PAT₹24 cr, vs ₹17 cr YoY
Consolidated business PAT₹17 cr, vs ₹5 cr YoY; remainder from FOREX, treasury income, exceptional gain
Standalone revenue₹170 cr, vs ₹155 cr YoY
Standalone EBITDA₹30 cr, vs ₹27 cr YoY
Standalone EBITDA margin14.4% (H1 FY27), absolute EBITDA improved 18%
Standalone gross margin45.9%, down 2.3 ppt YoY
Standalone PAT₹29 cr
Standalone business PAT₹20 cr, vs ₹18 cr YoY
BISP consolidated trailing 12-month revenue₹625 cr, 51% of consolidated top line
BISP standalone trailing 12-month revenue₹192 cr, 24% of standalone top line
BISP standalone EBITDA margin~10%
Consolidated H1 FY27 revenue₹653 cr, +17% YoY
Consolidated H1 FY27 EBITDA₹83 cr, vs ₹51 cr YoY
Consolidated H1 FY27 PAT₹64 cr, vs ₹59 cr YoY
Consolidated H1 FY27 business PAT₹49 cr, vs ₹31 cr YoY
Standalone H1 FY27 revenue₹411 cr, vs ₹384 cr YoY
Standalone H1 FY27 PAT₹57 cr, vs ₹65 cr YoY; business PAT higher YoY
Consolidated trailing 12-month ROCE143%, vs 57%; core capital employed ₹104 cr vs ₹322 cr, standalone ROCE is infinite
Consolidated return on net worth20%
Standalone return on net worth21%
Treasury₹468 cr, after repaying most Australian borrowings
Dividend declared in FY27₹3 per share, total payout ~₹21 cr; ₹2 interim in Q2, ₹1 interim post Q1, Q2 payout ~₹13 cr
IMPCO Mexico revenue₹40 cr, vs ₹17 cr YoY
GSK China revenue₹23 cr
Australia and USA combined revenue₹46 cr, vs ₹35 cr YoY
New product launchesRoom air conditioners, BLDC ceiling fans (7 models), air purifiers (2 models); asset-light, zero-CAPEX for ACs and fans